If clascoterone cream comes up during an acne appointment, bring your current skin-care products and medicine list. The discussion needs to cover the acne being treated, the rest of your routine and the prescription's precautions. Taking a GLP-1 medicine does not make an acne treatment automatically suitable.

Identify the medicine before adding it to the routine

The U.S. WINLEVI label identifies clascoterone 1% as an androgen receptor inhibitor for acne vulgaris in people aged 12 and older. [1]

Ask the clinician to name the condition being treated and the goal for review: fewer inflamed spots, fewer clogged pores, or another concern requiring separate assessment. Bring the exact cream name and strength rather than describing it only as a “hormonal cream.”

If your main concern is a change in facial shape, explain that separately. Do not let the appearance concern substitute for identifying which skin problem a prescription is intended to treat.

What did the facial-acne trials find?

Two double-blind, vehicle-controlled trials randomized 1,440 people aged nine or older with moderate or severe facial acne. At 12 weeks, adjusted success rates were 18.4% versus 9.0% and 20.3% versus 6.5%. Success required clear or almost-clear skin plus at least a two-point improvement on the investigator scale. [2]

Other acne medicines were excluded, so the trials do not establish the best combination routine. The authors noted limited subgroup evidence and a need for longer safety follow-up. Cassiopea funded the trials and manuscript and controlled study design, analysis and publication decisions; authors disclosed company employment or advisory ties. [2]

These are the paper's adjusted estimates, not a count of everyone whose acne improved to any degree. They describe a broader enrollment population than the U.S. labeled age range. Ask which evidence supports the combination your clinician proposes, rather than copying products from separate success stories.

Agree on what to do if the skin becomes irritated

The label warns of itching, burning, redness and peeling, and instructs discontinuation or reduced frequency if irritation occurs. It limits other irritating products and says not to apply to cuts, abrasions, eczema or sunburn. [1]

Before starting, show the prescriber your cleanser, exfoliant, retinoid, spot treatment and any facial devices. Ask which belong in the plan and which should be set aside. Get an answer about the actual products, not a general instruction to use “gentle actives.”

If irritation is happening now, contact the prescriber for advice on the treatment change. Note the product, application area, timing and symptoms so the conversation can address what you used.

Read the adrenal warning in its study context

The label reports test-defined suppression of the hypothalamic-pituitary-adrenal, or HPA, axis in 1/20 adults and 2/22 adolescents after two weeks in a pharmacokinetic study. Function was normal at follow-up four weeks after treatment ended. Larger treated areas, prolonged use and occlusive dressings can increase systemic absorption. [1]

This concerns the body's hormone-control system; it is a separate assessment from whether acne cleared. A small testing group does not provide a personal risk estimate or a reason to assume every user needs the same tests. Ask the prescriber whether your planned use needs any monitoring and whom to contact about concerns.

The patient information advises discussing pregnancy, breastfeeding, medical conditions and all medicines or supplements, and calling the provider about side effects. [1] Include your GLP-1 medicine on that list without guessing that it causes, prevents or changes this warning.

Keep supporting skin care manageable

AAD recommends a gentle, non-abrasive cleanser applied with fingertips, avoiding scrubbing and frequent treatment switching. For sun protection it recommends shade, protective clothing and broad-spectrum, water-resistant SPF 30 or higher; sunscreen can be labeled non-comedogenic. [3]

Write the agreed routine on one page and keep a copy with the prescription information. At review, bring the routine you actually followed and the changes you noticed. Ask when to reassess benefit and tolerability rather than continuing to add products between visits.

Our face-washing guide covers cleansing technique, while the dark-marks guide addresses a separate appearance concern. Neither replaces the medication-specific plan.

This article provides general education, not a diagnosis or an individual treatment plan. Medication information refers to US sources. Discuss medication, nutrition and cosmetic treatment decisions with qualified clinicians.

Sources

  1. WINLEVI: clascoterone cream, U.S. prescribing and patient informationDailyMed; label posted January 2025, prescribing information July 2022; checked October 2026↩ Back to text
  2. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical TrialsHebert and colleagues, JAMA Dermatology, April 2020↩ Back to text
  3. Acne: Tips for managingAmerican Academy of Dermatology; updated November 2022, checked October 2026↩ Back to text